Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Breast Neoplasms 92Neoplasms 87Lung Neoplasms 55Prostatic Neoplasms 48Colorectal Neoplasms 42Carcinoma, Non-Small-Cell Lung 35Pancreatic Neoplasms 24Multiple Myeloma 24Stomach Neoplasms 21Hematologic Neoplasms 21Carcinoma, Hepatocellular 19Ovarian Neoplasms 18Melanoma 17Lymphoma 16Leukemia, Myeloid, Acute 16Esophageal Neoplasms 16Brain Neoplasms 16Urinary Bladder Neoplasms 13Liver Neoplasms 13Colonic Neoplasms 13Uterine Cervical Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Neoplasm Metastasis 12Leukemia, Lymphocytic, Chronic, B-Cell 12Leukemia 12Kidney Neoplasms 12Head and Neck Neoplasms 12Endometrial Neoplasms 12Disease 12Recurrence 11

Interventions

Olanzapine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Vomiting × 30 days × Clear all
NCT07403370 2026-05-19

Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis

Shandong Cancer Hospital and Institute

Completed
2,000 enrolled

Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡